

**AMENDMENTS TO THE SPECIFICATION**

Please amend the specification as follows. Paragraphs replaced and amended as set forth below contain amendments made for the first time in this response. A full set of all paragraphs amended during the pendency of this reissue application is present in APPENDIX I.

Please replace the text at Column 2 lines 42-51 in the specification with the following amended paragraph:

Sakamoto et al., U.S. Pat. No. 4,579,827 (Apr. 1, 1986), discloses a number of mAbs said to be useful for diagnosing or treating human colon cancer by a number of different approaches. None of these mAbs is shown to react with a human colon carcinoma-associated antigen that is a protein of [either] 61 [or 72] kDa molecular weight, distinguishing these antibodies from the [antibodies] 33.28 antibody of the present invention (described below). Furthermore, none of the Sakamoto mAbs have the degree of colon tumor specificity of the mAbs disclosed in the present application.

Please replace the text at Column 4 lines 3-14 in the specification with the following amended paragraph:

In one embodiment, the antibody is specific for a CCAA which is a protein having a molecular weight of about 61 kilodaltons. [In another embodiment, the antibody is specific for a CCAA which is a protein having a molecular weight of about 72 kilodaltons.] In a preferred embodiment, the antibody is the mouse monoclonal antibody 33.28 or 31.1 or an antibody which binds specifically to the same colon carcinoma-associated epitope as that bound by 33.28 or 31.1. In another preferred embodiment, the antibody is a mouse/human chimeric antibody Chi #1

that binds specifically to the same colon carcinoma-associated epitope as that bound by 31.1.

Please replace the text at Column 25 lines 48-56 in the specification with the following amended paragraph:

The molecular mass of the antigens to which the above mAbs bound was determined by Western blot analysis using soluble protein extracted from colon carcinoma cell lines SW480 and SW620. The 33.28 [and 31.1 mAbs] antibody reacted with molecules having an apparent molecular [weights] weight of 61.1 kDa[ and 72 kDa, respectively], from both of these cells lines. [These mAbs] The 33.28 and 31.1 mAbs did not react with material from human PBMCs or from human tumor cell lines of other histologic types in Western blot analysis.